# Denise A. Yardley

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/denise-a-yardley/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,323 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 68 |
| i10-index | 191 |
| Last Known Institution | Sarah Cannon Research Institute |
| OpenAlex ID | https://openalex.org/A5022422153 |
| ORCID iD | https://orcid.org/0000-0002-8664-3458 |
| Works | 562 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer](https://scholariq.org/papers/monarch-1-a-phase-ii-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer](https://scholariq.org/papers/a-phase-ii-study-of-abemaciclib-in-patients-with-brain-metastases-secondary-to/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Sarah Cannon Research Institute](https://scholariq.org/institutions/sarah-cannon-research-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.